16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2817-2827

  Ducès, Aurélie ^a   Karaky, Racha ^b   Martel Renoir, Dominique ^b   Mir, Lluis ^b   Hamma Kourbali, Yamina ^c   Biéche, Ivan ^a   Opolon, Paule ^b   Delbé, Jean ^c   Courty, José ^c   Perricaudet, Michel ^b,d   Griscelli, Frank ^a  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Université Paris XII Val de Marne ^*  (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA TOPOISOMERASE (ATP HYDROLYSING); GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MESSENGER RNA; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLEIOTROPHIN; PLEIOTROPHIN DELTA [111-136]; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CARCINOGENIC ACTIVITY; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; GENE DELETION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOGENESIS; MOUSE; MUSCLE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR VOLUME; WILD TYPE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, NUDE; MOLECULAR WEIGHT; MUTANT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049144741     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0301     Document Type: Article

References (42)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Bernard-Pierrot I, Delbé J, Rouet J, et al. Dominant negative effectors of heparin affin regulatory peptide (HARP) angiogenic and transforming activities. J Biol Chem 2002;277:32071-7.
3. Courty J, Dauchel MC, Caruelle D, Perderiset M, Barritault D. Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem Biophys Res Commun 1991;180:145-51.
4. Fang W, Hartmann N, Chow DT, Riegel AT, Wellstein A. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem 1992;267:25889-97.
5. Laaroubi K, Delbe J, Vacherot F, et al. Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors 1994;10:89-98.
6. Papadimitriou E, Polykratis A, Courty J, Koolwijk P, Heroult M, Katsoris P. HARP induces angiogenesis in vivo and in vitro: implication of N or C terminal peptides. Biochem Biophys Res Commun 2001;282:306-13.
7. Souttou B, Juhl H, Hackenbruck J, et al. Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst 1998;90:1468-73.
8. Chauhan AK, Li YS, Deuel TF. Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc Natl Acad Sci U S A 1993;90:679-82.
9. Bernard-Pierrot L, Heroult M, Lemaitre G, Barritault D, Courty J, Milhiet PE. Glycosaminoglycans promote HARP/PTN dimerization. Biochem Biophys Res Commun 1999;266:437-42.
10. Muramatsu T. Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis [review]. J Biochem 2002;132:359-71.
11. Chen S, Bu G, Takei Y, et al. Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells. J Cell Sci 2007;15:4009-15.
12. Mueller S, Kunkel P, Lamszus K, et al. A role for receptor tyrosine phosphatase ζ in glioma cell migration. Oncogene 2003;22:6661-8.
13. Maeda N, Nishiwaki T, Shintani T, Hamanaka H, Noda M. 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase ζ/RPTPβ, binds pleiotrophin/heparin- binding growth-associated molecule (HB-GAM). J Biol Chem 1996;30:21446-52.
14. Bermek O, Diamantopoulou Z, Polykratis A, et al. A basic peptide derived from the HARPC-terminus inhibits anchorage-independent growth of DU145 prostate cancer cells. Exp Cell Res 2007;15:4041-50.
15. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-9.
16. Bowden ET, Stoica GE, Wellstein A. Anti-apoptotic signaling of pleiotrophin through its receptor anaplastic lymphoma kinase. J Biol Chem 2002;277:35862-8.
17. Bernard-Pierrot L, Delbé J, Caruelle D, Barritault D, Courty J, Milhiet PE. The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activity. J Biol Chem 2001;276:12228-34.
18. Galaup A, Magnon C, Rouffiac V, et al. Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice. Gene Ther 2005;12:831-42.
19. Berthebaud M, Riviere C, Jarrier P, et al. RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood 2005;106:2962-8.
20. Vacherot F, Delbé J, Heroult M, Barritault D, Fernig DG, Courty J. Glycosaminoglycans differentially bind HARP and modulate its biological activity. J Biol Chem 1999;274:7741-7.
21. Soulié P, Héroult M, Bernard-Pierrot I, et al. Correlation of elevated plasma levels of two structurally related growth factors, heparin affin regulatory peptide and midkine in advanced solid tumor patients. Cancer Detect Prev 2004;8:319-24.
22. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001;61:1652-8.
23. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-56.
24. Hamma-Kourbali Y, Bernard-Pierrot I, Heroult M, et al. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-Idomain. J Cell Physiol 2008;214:250-9.
25. Martel-Renoir D, Tronchon-Joseph V, Galaup A, et al. Coelectro-transfer of three plasmids coding for antiangiogenic factors and regulatory factors of the tetracycline-inducible system: tightly regulated expression, inhibition of transplanted tumor growth, and antimetastatic effect. Mol Ther 2003;8:425-33.
26. Marot D, Opolon P, Brailly-Tabard S, et al. The tumor suppressor activity induced by adenovirus-mediated BRCA1 overexpression in not restricted to breast cancers. Gene Ther 2006;13:235-44.
27. Elie N, Plancoulaine B, Signolle JP, Herlin P. A simple way of quantifying immunostained cell nuclei on the whole histologic section. Cytometry A 2003;56:37-45.
28. Tursz T, Le Cesne AL, Baldeyrou P, et al. Phase Istudy of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996;88:1857-63.
29. Weber D, Klomp HJ, Czubayko F, Wellstein A, Juhl H. Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res 2000;60:5284-8.
30. Czubayko F, Schulte AM, Berchem GJ, Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci U S A 1996;93:14753-8.
31. Jager R, Noll K, Havemann K, Knabbe C, Rauvala H, Zugmaier G. Differential expression and biological activity of the heparin-binding growth-associated molecule (HB-GAM) in lung cancer cell lines. Int J Cancer 1997;73:537-43.
32. Garver R, Radford D, Donis-Keller Wick M, Milner P. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994;74:1584-90.
33. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethilenimine-complexed small interfering RNAs in vivo exerts antitumoral effects on glioblastoma xenografts. Hum Gene Ther 2006;17:751-66.
34. Foehr E, Lorente G, Kuo J, Karoly R, Urfer R. Targeting of the receptor protein tyrosine phosphate β with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 2006;66:2271-8.
35. Maeda N, Noda M. Involvement of receptor-like protein tyrosine phosphatase ζ/RPTPβ and its ligand pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in neuronal migration. J Cell Biol 1998;13:203-16.
36. Pariser H, Ezquerra L, Herradon G, Perez-Pinera P, Deuel TF. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase β/ζ-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 2005;332:664-9.
37. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997;1:1814-9.
38. Héroult M, Bernard-Pierrot I, Delbé J, et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. Oncogene 2004;4:1745-53.
39. Land S, Tee A. Hypoxia inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR-signalling motif. J Biol Chem 2007;13:20534-43.
40. Thomas G, Tran C, Mellinghoff I, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7.
41. Polykratis A, Delbé J, Courty J, Papadimitriou E, Katsoris P. Identification of heparin affin regulatory peptide domains with potential role on angiogenesis. Int J Biochem Cell Biol 2004;10:1954-66.
42. Dean RA, Butler GS, Hamma-Kourbali Y, et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol 2007;24:8454-65.